menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Alpine Immune Sciences Reports First Quarter 2024 Financial Results

    BUSINESSWIRE

    Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications

    ENDPTS

    Alpine Immune Sciences, Janux said to be looking at possible sales — reports

    ENDPTS

    Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

    BUSINESSWIRE

    Alpine Immune Sciences Shares Clinical Data on Povetacicept

    BUSINESSWIRE

    Alpine to Present Updated Clinical Data for Povetacicept in WCN 2024

    BUSINESSWIRE

    Alpine Presents New Translational Data on Povetacicept at the EU Meeting 2024

    BUSINESSWIRE

    Alpine Immune Sciences to Participate in Upcoming Virtual Conference

    BUSINESSWIRE

    Alpine Immune Provides Corporate Update and Full Year 2023 Financial Results

    BUSINESSWIRE

    Alpine Immune to Report Fourth Quarter and Full Year 2023 Financial Results

    BUSINESSWIRE

    Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences

    BUSINESSWIRE

    Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences

    BUSINESSWIRE

    AbbVie agrees to end Alpine study early in return for fee cuts

    FIERCE BIOTECH

    Alpine Immune Sciences Announces Amendment of Acazicolcept Option with AbbVie

    BUSINESSWIRE

    Alpine Immune to Present at the 42nd Annual J.P. Morgan Healthcare Conference

    BUSINESSWIRE

    Alpine Immune Up 8.60%: This Is What Analysts Are Now Forecasting

    STOCK REGISTER

    Alpine Immune Sciences to Participate in the Evercore ISI HealthconX Conference

    BUSINESSWIRE

    Alpine Immune Sciences Presents New Translational Data on Povetacicept

    BUSINESSWIRE

    Alpine Immune Sciences Reports Third Quarter 2023 Financial Results

    BUSINESSWIRE

    Alpine Immune Presents Data on Acazicolcept in Systemic Lupus Erythematosus

    PRESS RELEASE

    Alpine Immune Sciences Announces Proposed Public Offering

    BUSINESSWIRE

    Alpine Immune Sciences Announces Pricing of $150 Million Public Offering

    BUSINESSWIRE

    Alpine Immune Presents New Preclinical Data on Povetacicept in Myasthenia Gravis

    BUSINESSWIRE

    Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept

    BUSINESSWIRE

    Alpine Immune Sciences to Present New Translational Data on Povetacicept

    BUSINESSWIRE

    Alpine Immune Sciences to Present Initial Clinical Data on Povetacicept

    BUSINESSWIRE

    Alpine Immune Announces Appointment of Wolfgang Dummer as CMO

    BUSINESSWIRE

    Alpine Immune Sciences Presents First Preclinical Data for Povetacicept

    BUSINESSWIRE

    Alpine Immune to Present Data for Povetacicept in Myasthenia Gravis

    BUSINESSWIRE

    Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences

    BUSINESSWIRE

    Alpine Immune Sciences Announces Initiation of Dosing in 240 mg IgA Nephropathy

    BUSINESSWIRE

    Alpine Immune Sciences Announces Appointment of M. Christina Yi as CTO

    BUSINESSWIRE

    Alpine Immune Sciences Reports Second Quarter 2023 Financial Results

    BUSINESSWIRE

    Alpine Immune Sciences to Present Data from RUBY-1

    BUSINESSWIRE

    Alpine Immune Sciences Reports First Quarter 2023 Financial Results

    BUSINESSWIRE

    Alpine Immune Sciences Announces Participation in the Bank of America Securities

    BUSINESSWIRE

    Alpine Immune Reports Fourth Quarter and Full Year 2022 Financial Results

    BUSINESSWIRE

    Alpine Immune Sciences to Present Povetacicept Phase 1 Study Data at Conferences

    BUSINESSWIRE

    Alpine Immune Sciences to Present Povetacicept Phase 1 Study Data

    BUSINESSWIRE

    Alpine Immune to Report Fourth Quarter and Full Year 2022 Financial Results

    BUSINESSWIRE

    Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences

    BUSINESSWIRE

    Alpine Immune to Participate in the SVB Securities Global Biopharma Conference

    BUSINESSWIRE

    Alpine Immune Sciences Announces Participation in Fireside Chat

    BUSINESSWIRE

    Alpine Reports Third Quarter 2022 Financial Results

    BUSINESSWIRE

    Alpine Immune Sciences to Report Third Quarter 2022 Financial Results

    BUSINESSWIRE

    Alpine Immune to Present ALPN-303 PhI Study Data at 2022 ASH Meeting

    BUSINESSWIRE

    Alpine Immune Sciences Presents Update Of ALPN-303 Ph1 (RUBY-1) Clinical Data

    BUSINESSWIRE

    Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data

    BUSINESSWIRE

    Alpine bails on phase 1 cancer asset after 2nd patient death

    FIERCEBIOTECH

    Alpine Immune Sciences Announces Pricing of $100 Million Public Offering

    BUSINESSWIRE

    Alpine to Highlight Clinical Updates on Autoimmune and Immuno-Oncology Programs

    BUSINESSWIRE

    Alpine Immune Sciences Announces Participation in September Investor Conferences

    BUSINESSWIRE

    Alpine Announces R&D Day to Provide Clinical Updates on ALPN-303 & Davoceticept

    BUSINESSWIRE

    Alpine Announces Inducement Grant to Andrew S. Sandler

    BUSINESSWIRE

    Alpine Immune Sciences Reports Second Quarter 2022 Financial Results

    BUSINESSWIRE

    Evotec and Alpine Expand Partnership for Development of ALPN-303

    BUSINESSWIRE

    Just - Evotec Biologics, Alpine Immune Sciences Expand Partnership for ALPN-303

    ACCESSWIRE

    Alpine Immune Sciences to Participate in Fireside Chat at Wedbush Conference

    BUSINESSWIRE

    Alpine Immune Sciences Appoints Jörn Drappa, MD, PhD, to Board of Directors

    BUSINESSWIRE

    Alpine Immune Sciences Appoints Andrew S. Sandler, M.D. as Chief Medical Officer

    BUSINESSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.